As of 3:59pm ET
| +0.27 / +2.37%|
Endo International Plc operates as a pharmaceutical company. It focuses on developing, manufacturing, and distributing of branded and generic pharmaceutical products. The company operates through the following segments: U.S. Branded Pharmaceuticals, U.S. Generic pharmaceuticals and International Pharmaceuticals. The U.S. Branded Pharmaceuticals offers products that focus on the treatment and management of conditions in urology, urologic oncology, endocrinology, and orthopedics. The U.S. Generic pharmaceuticals segment consist of a differentiated product portfolio including high-barrier-to-entry products, first-to-file or first-to-market opportunities that are difficult to formulate, difficult to manufacture or face complex legal and regulatory challenges. The International Pharmaceuticals segment includes a variety of pharmaceutical products for the Canadian, Latin American, South African, and world markets. Endo International was founded on October 31, 2013 and is headquartered Dublin, Ireland.
|Paul V. Campanelli||President, Chief Executive Officer & Director|
|Terrance J. Coughlin||Chief Operating Officer & Executive Vice President|
|Blaise Coleman||Chief Financial Officer & Executive Vice President|
|Robert J. Cobuzzi||SVP-Operations, Research & Development Strategy|
|Jennifer E. Dubas||Vice President & Chief Compliance Officer|